Climb Bio, Inc. Common Stock (CLYM)

• Market cap: $135M
• 1 day: -2.45%
• 5 days: -14.59%
• 1 month: -5.69%
• 3 months: 56.69%
• 6 months: 42.14%
• Year to date: -3.86%
• 1 year: -75.85%
• 5 years: -87.48%
• 10 years: -87.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2% less capital invested

Capital invested by funds: $63.4M [Q1] → $61.9M (-$1.5M) [Q2]

3.13% less ownership

Funds ownership: 76.97% [Q1] → 73.83% (-3.13%) [Q2]

11% less funds holding

Funds holding: 76 [Q1] → 68 (-8) [Q2]

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

31% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 26

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9
• Avg. target: $9
• High target: $9

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Baird Colleen Kusy

$9

Outperform Initiated

15 Aug 2025